ATE355057T1 - Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen - Google Patents

Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Info

Publication number
ATE355057T1
ATE355057T1 AT96901620T AT96901620T ATE355057T1 AT E355057 T1 ATE355057 T1 AT E355057T1 AT 96901620 T AT96901620 T AT 96901620T AT 96901620 T AT96901620 T AT 96901620T AT E355057 T1 ATE355057 T1 AT E355057T1
Authority
AT
Austria
Prior art keywords
amino acids
disorders
movement disorders
aromatic
branched amino
Prior art date
Application number
AT96901620T
Other languages
English (en)
Inventor
Mary Ann Richardson
Original Assignee
New York State Office Of Menta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23462994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE355057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York State Office Of Menta filed Critical New York State Office Of Menta
Application granted granted Critical
Publication of ATE355057T1 publication Critical patent/ATE355057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96901620T 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen ATE355057T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/371,211 US5670539A (en) 1993-07-21 1995-01-11 Treatment of movement disorders using large neutral amino acids

Publications (1)

Publication Number Publication Date
ATE355057T1 true ATE355057T1 (de) 2006-03-15

Family

ID=23462994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901620T ATE355057T1 (de) 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Country Status (6)

Country Link
US (2) US5670539A (de)
EP (1) EP0799034B1 (de)
AT (1) ATE355057T1 (de)
CA (1) CA2210233A1 (de)
DE (1) DE69636934D1 (de)
WO (1) WO1996021437A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
RU2151596C1 (ru) * 1999-03-10 2000-06-27 Казанский государственный университет им. В.И. Ульянова-Ленина Композиция аминокислот с микроэлементами и кальцием, обладающая противоопухолевой, антидепрессивной и противоаритмической активностью
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
WO2004016261A1 (en) * 2002-08-12 2004-02-26 Yuuichi Murayama Method for suppressing proliferation of abnormal prion protein with leucine, isoleucine or valine
US20060094785A1 (en) * 2002-07-12 2006-05-04 Guttuso Jr Thomas J Use of amino acids for treatment of various conditions
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
JP4651078B2 (ja) * 2003-03-10 2011-03-16 雅美 森山 異常プリオン蛋白質の増殖の抑制方法
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
CN101945653B (zh) * 2008-01-02 2013-01-16 海洋生物有限公司 用于治疗神经变性疾病的组合物和方法
HK1220622A1 (zh) * 2013-03-14 2017-05-12 Janssen Pharmaceutica, N.V. Gpr139的生理性配体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4129652A (en) * 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) * 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4296119A (en) * 1978-04-24 1981-10-20 Massachusetts Institute Of Technology Process and composition for reducing blood pressure in animals
US4209531A (en) * 1978-09-13 1980-06-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4438144A (en) * 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US5028622A (en) * 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5006559A (en) * 1988-08-31 1991-04-09 Clintec Nutrition Co. Method of use of branched-chain amino acids infusions to influence appetite
US5206218A (en) * 1989-04-03 1993-04-27 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5393784A (en) * 1993-07-21 1995-02-28 New York State Office Of Mental Health Treatment of tardive dyskinesia with leucine, isoleucine, valine or mixtures thereof

Also Published As

Publication number Publication date
DE69636934D1 (de) 2007-04-12
US5670539A (en) 1997-09-23
EP0799034B1 (de) 2007-02-28
EP0799034A4 (de) 2002-05-22
CA2210233A1 (en) 1996-07-18
EP0799034A1 (de) 1997-10-08
US5919823A (en) 1999-07-06
WO1996021437A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
HU9600832D0 (en) Inhibitors of beta-amyloid protein production
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
MXPA03010911A (es) Anticuerpos contra ngf para el tratamiento de varios desordenes.
HUT65754A (en) Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
HU9502585D0 (en) Use of riluzole for treating aids-related neural disorders
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
IL129178A0 (en) Induction of nerve generation
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE260108T1 (de) Verwendung von citicoline zur behandlung von multipler sklerose
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
ATE209005T1 (de) Verwendung von threonin zur behandlung der phenylketonurie
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
ATE249229T1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties